Daré Bioscience, Inc (DARE)

Etorro trading 970x250
Daré Bioscience, Inc (DARE) Logo

About Daré Bioscience, Inc

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women’s health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company’s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California. Address: 3655 Nobel Drive, San Diego, CA, United States, 92122

Daré Bioscience, Inc News and around…

Latest news about Daré Bioscience, Inc (DARE) common stock and company :

Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
04 Jan, 2022 Yahoo! Finance

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright BIOCONNECT 2022 Conference being held virtually January 10 – 13, 2022. Ms. Johnson’s presentation will be available on-demand for conference participants, and under “Presentations, Events & Webcasts" in the Investors section of t

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Dec, 2021 FinancialContent

Gainers Orchard Therapeutics (NASDAQ:ORTX) stock moved upwards by 12.6% to $1.34 during Wednesday's pre-market ...

12 Health Care Stocks Moving In Monday's After-Market Session
27 Dec, 2021 FinancialContent

Gainers OptiNose (NASDAQ:OPTN) shares moved upwards by 9.81% to $1.79 during Monday's after-market session. Trading volume for this ...

Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
09 Dec, 2021 Yahoo! Finance

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
09 Dec, 2021 FinancialContent

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
09 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

35 Stocks Moving In Wednesday's Mid-Day Session
08 Dec, 2021 FinancialContent

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement ...

Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today?
08 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are still a hot topic among retail traders and we're covering some of the top ones to watch Wednesday that are on the move. The post Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

BZ Chart Of The Day: Dare Bioscience
08 Dec, 2021 FinancialContent

If markets have memories, shares of DarBioscience, Inc. (NASDAQ: DARE) may be in trouble. The stock has run into a resistance ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
08 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

22 Stocks Moving in Wednesday's Pre-Market Session
08 Dec, 2021 FinancialContent

Gainers DarBioscience, Inc. (NASDAQ: DARE) rose 45.2% to $3.08 in pre-market trading after the company reported the FDA ...

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
07 Dec, 2021 Yahoo! Finance

Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré’s portfolio of potential first in category development candidates Strategic partnering discussions ongoing; Conference call will be scheduled once a definitive partnership agreement for commercialization of XACIATO in the U.S. is finalized and executed; U.S. commercial launch expected 2022 SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE

Daré Bioscience's One-Time Bacterial Vaginosis Treatment Scores FDA Approval
07 Dec, 2021 FinancialContent

TheFDA has approvedDarBioscience Inc(NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial ...

The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
07 Dec, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive ...

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
06 Dec, 2021 FinancialContent

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt ...

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
02 Dec, 2021 FinancialContent

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, ...

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
14 Nov, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of -63.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To ...

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
10 Nov, 2021 Yahoo! Finance

Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 Actively advancing clinical development and strategic partnerships to maximize value of pipeline candidates Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financia

Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
09 Nov, 2021 Yahoo! Finance

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference being held November 15-17, 2021. Date:Tuesday, November 16thTime:3:20 p.m. ETPresenter:Sabrina Martucci Johnson, President and Chief Executive OfficerLive webcast:https://wsw.com/webcast/stifel58/dare/1859760 An archived webca

Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
03 Nov, 2021 Yahoo! Finance

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, November 10, 2021, to review its financial results for the quarter ended September 30, 2021 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is

Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
06 Oct, 2021 Yahoo! Finance

An interactive conversation regarding the importance of industry and investor commitment to women’s health innovationSAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health Summit being held in Boston, MA from October 12 – 14, 2021, at The Westin Copley Place. “I’m excited to be part of an esteemed panel of women to discuss the commitment and participation of

12 Health Care Stocks Moving In Tuesday's After-Market Session
28 Sep, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) shares rose 46.37% to $6.06 during Tuesday's after-market session. This security traded at a ...

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
27 Sep, 2021 FinancialContent

DARE-LARC1 Aims to Combine the Benefits of Long-acting Reversible Contraception with User-Controlled Flexibility to Pause or Resume Contraception as Desired

Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
24 Sep, 2021 Yahoo! Finance

Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
23 Sep, 2021 FinancialContent
Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
22 Sep, 2021 FinancialContent
Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent
Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit
07 Sep, 2021 FinancialContent

Daré Bioscience, Inc (DARE) is a NASDAQ Common Stock listed in , ,

970x250